# FDA 483 - Mary Kay, Inc - July 19, 2019

Source: https://www.keypedia.com/records/483/mary-kay-inc/7579fde1-a80c-4e4f-ba13-7ff2cddf7444

> FDA 483 for Mary Kay, Inc on July 19, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Mary Kay, Inc
- Inspection Date: 2019-07-19
- Product Type: drugs
- Office Name: Dallas District Office
- Summary: An FDA inspection of Mary Kay, Inc.'s OTC drug facility in Dallas, TX, revealed three significant observations. These included failures in preventing contamination during component handling and storage, inadequate visual examination of incoming component containers for damage, and deficient procedures for equipment cleaning and maintenance. The findings indicate issues with quality control and adherence to good manufacturing practices.

## Related Officers

- [Wilmary Negron Rodriguez](https://www.keypedia.com/people/wilmary-negron-rodriguez/e7bb04eb-ed58-4e4c-932d-1069c76c0215)

Company: https://www.keypedia.com/companies/mary-kay-inc/90637110-bda9-4a64-8210-062bfc805ac4

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9